This website is an independent initiative of the historic and founding shareholders of OSE Immunotherapeutics. It is not the company's corporate website. Its purpose is to inform other shareholders and stakeholders about our positions and proposals in the context of the debate on strategy and governance.

News

Open Letter to the Shareholders of OSE Immunotherapeutics (OSE) Our vision as founding shareholders and former executives acting in concert
Chercheurs en laboratoire

Open Letter to the Shareholders of OSE Immunotherapeutics (OSE) Our vision as founding shareholders and former executives acting in concert

Read all
1920 1024 OSE Immuno Together
The three founding shareholders deplore the headlong rush and misinformation of OSE’s current Board of Directors.
Loria Costantini Peyroles

The three founding shareholders deplore the headlong rush and misinformation of OSE’s current Board of Directors.

Read all
1536 1024 OSE Immuno Together
General Meeting of September 30: The three founding shareholders call for a complete renewal of the Board of Director

General Meeting of September 30: The three founding shareholders call for a complete renewal of the Board of Director

Read all
1536 1024 OSE Immuno Together
Open Letter from Dominique Costantini, Emile Loria, and Alexis Peyroles

Open Letter from Dominique Costantini, Emile Loria, and Alexis Peyroles

Read all
1536 1024 OSE Immuno Together
Reaction of the Three Founding and Concerted Shareholdersto the Latest Announcements from OSE Immunotherapeutics
Communique de presse

Reaction of the Three Founding and Concerted Shareholdersto the Latest Announcements from OSE Immunotherapeutics

Read all
1920 1281 OSE Immuno Together
Launch of ose-immuno-ensemble.com to inform all stakeholders of OSE Immunotherapeutics ahead of the September 30, 2025 General Meeting
Press release

Launch of ose-immuno-ensemble.com to inform all stakeholders of OSE Immunotherapeutics ahead of the September 30, 2025 General Meeting

Read all
1920 1281 OSE Immuno Together
Shareholder note dated June 20, 2025, informing about our action to contest the extension until September 30, 2025, for holding the General Meeting.

Shareholder note dated June 20, 2025, informing about our action to contest the extension until September 30, 2025, for holding the General Meeting.

Read all
1536 1024 OSE Immuno Together
  • 1
  • 2